MIF and cancer: Additionally, since oxMIF was also specifically found to be expressed—using immunohistochemistry methods, which prevented an experimentally-induced conversion of MIF to oxMIF (e.g., by fixatives or oxidative agents)—in primary tumors (e.g., colorectal, lung, ovarian, and pancreatic) but not in adjacent non-tumoral tissues [26], it is considered a potential marker and target for cancer therapy [26,27].